Elanco Animal Health (ELAN)
NYSE Market Closed
Elanco Animal Health is a global animal health company that develops, manufactures, and markets medicines, vaccines, parasiticides, nutritional products, and other health solutions for companion animals and livestock. The company was separated from Eli Lilly in 2018, giving it an independent public-market identity after decades of operating within a large pharmaceutical group. It has expanded through acquisitions, including the purchase of Bayer Animal Health, which broadened its presence in pet health and strengthened its international product portfolio.
Elanco serves two main markets. In companion animals, it provides products for dogs, cats, and other pets, including treatments for fleas, ticks, worms, pain, dermatology, and disease prevention. This segment benefits from the trend of pet owners spending more on animal wellbeing and veterinary care. In food animals, the company supplies products used in cattle, poultry, swine, sheep, and aquaculture production, helping producers manage disease, improve animal welfare, and support efficient protein supply chains.
The business operates in more than 90 countries and sells through veterinarians, farm supply channels, distributors, retailers, and other animal health networks. Its competitive landscape includes large animal health specialists as well as diversified pharmaceutical and agricultural companies. Research and development, regulatory approvals, product safety, and relationships with veterinarians and livestock producers are central to its position.
For investors, Elanco provides exposure to durable demand for pet care and global animal protein production. At the same time, its results can be affected by competition from generics, commodity livestock cycles, regulatory changes, foreign exchange, integration of acquisitions, debt levels, and the pace at which new animal health products reach the market.
Last updated
- Market Cap
- 11.42B
- P/E
- —
- P/FCF
- 36.26
- P/S
- 2.33
- Enterprise Value
- 14.99B
- Sector
- Materials
- Industry
- Pharmaceutical Preparations
- Address
- 450 ELANCO CIRCLE, INDIANAPOLIS, IN, 46221
The Glucosamine Supplements for Dogs Market, Global Forecast 2026-2032 | Innovation Drives Canine Glucosamine Supplement Market with New Chewable and Liquid Formats
Canine Vaccines Market Size to Reach USD 3.45 Billion by 2033, Supported by Rising Pet Ownership and Preventive Animal Healthcare Focus – SNS Insider
Diesel Generator Market is expected to generate a revenue of USD 27.42 Billion by 2032, Globally, at 5.28% CAGR: Verified Market Research®
VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm
Companion Animal Health Market to Worth USD 61.74 Billion by 2034, Driven by Rising Pet Ownership and Humanization Trends
Pet Cancer Therapeutics Market Size Worth USD 1,150.70 Million by 2034
Veterinary Oncology Market Shares, Competition and Trends Analysis 2025-2030: Discover the Impact of Advanced Therapies and Digital Tools
Animal Health Market Trends, Key Player Strategies, and Growth Outlook to 2034 - Zoonotic Disease Prevention, Digital Diagnostic Tech, and Sustainable Antibiotic Alternatives are Key Areas
Shareholder Alert: Johnson Fistel, LLP Investigates Elanco Animal Health, Masimo, Fidelity National Information, and Super Micro Computer —Long-Term Investors are Encouraged to Contact the Firm
Shareholder Alert: Johnson Fistel, LLP Investigates Elanco Animal Health, Fox Factory Holding, Fidelity National Information, and Bank of America —Long-Term Investors are Encouraged to Contact the Firm
Poultry Vaccine & Drug Market Booming as Demand for Disease Prevention Increases
Growth Trends in the Porcine Vaccines Market, Forecast to 2028: Increasing Government Initiatives for Funding Animal Husbandry
ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ELAN DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Elanco Animal Health Incorporated Investors to Secure Counsel Before Important December 6 Deadline in Securities Class Action – ELAN
ELAN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elanco Animal Health Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ELAN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Elanco Animal Health Incorporated Investors to Secure Counsel Before Important December 6 Deadline in Securities Class Action – ELAN
Elanco (ELAN) Hit with Investor Lawsuit Over New Drug, December 6th Deadline Pending – Hagens Berman
ELAN LEGAL DEADLINE: Elanco Animal Health Class Action Deadline is Approaching – Contact BFA Law if You Suffered Losses (NYSE:ELAN)
ELAN LEGAL UPDATE: A Lawsuit has been Filed Against Elanco Animal Health for Securities Fraud - Contact BFA Law before Court Deadline (NYSE:ELAN)
Elanco Animal Health Incorporated Investors: Please contact the Portnoy Law Firm to recover your losses. December 6, 2024 Deadline to file Lead Plaintiff Motion
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 11.42B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 14.99B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 1.76
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 2.33
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 15.26
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 3.06
- EPS
- -0.48
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 36.26
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 19.8
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 315M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -3.72%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -1.83%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.61
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.82
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 0.95
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.22
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 7.04M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 22.87
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 1.37B | 1.14B | 1.14B | 1.24B | 1.19B |
| Gross profit | 785M | 589M | 607M | 713M | 684M |
| Operating income | 144M | -183M | 2M | 84M | 100M |
| EBITDA | 332M | 193M | 203M | 254M | 270M |
| Net income | 57M | -276M | -34M | 11M | 67M |
| Basic EPS | 0.11 | -0.56 | -0.07 | 0.02 | 0.14 |
| Diluted EPS | 0.11 | -0.56 | -0.07 | 0.02 | 0.13 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 13.22B | 13.36B | 13.55B | 13.74B | 12.94B |
| Total liabilities | 6.72B | 6.81B | 6.8B | 6.97B | 6.59B |
| Total equity | 6.5B | 6.55B | 6.75B | 6.78B | 6.35B |
| Cash & equivalents | 428M | 545M | 505M | 539M | 487M |
| Current assets | 3.58B | 3.46B | 3.49B | 3.61B | 3.44B |
| Current liabilities | 1.97B | 1.9B | 1.76B | 1.69B | 1.27B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 13M | 108M | 219M | 237M | -4M |
| Investing cash flow | -60M | -64M | -101M | -56M | -58M |
| Financing cash flow | -65M | -18M | -153M | -156M | 52M |
| Change in cash | -117M | 40M | -34M | 52M | 19M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — VanHimbergen Robert M | View Filing | |
| form 4 | Form 4 — Modi Rajeev A. | View Filing | |
| edgar index | 8-K — Elanco Animal Health Inc | View Filing | |
| edgar index | SD — Elanco Animal Health Inc | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| form 4 | Form 4 — GARCIA ART A | View Filing | |
| form 4 | Form 4 — GARCIA ART A | View Filing | |
| form 4 | Form 4 — HOOVER R DAVID | View Filing | |
| form 4 | Form 4 — HOOVER R DAVID | View Filing | |
| form 4 | Form 4 — HOOVER R DAVID | View Filing | |
| form 4 | Form 4 — Scots-Knight Denise | View Filing | |
| form 4 | Form 4 — Scots-Knight Denise | View Filing | |
| form 4 | Form 4 — Kurzius Lawrence Erik | View Filing | |
| form 4 | Form 4 — Kurzius Lawrence Erik | View Filing | |
| form 4 | Form 4 — Herendeen Paul | View Filing | |
| form 4 | Form 4 — Herendeen Paul | View Filing | |
| form 4 | Form 4 — Kochevar Deborah Turner | View Filing | |
| form 4 | Form 4 — McDonald Kirk P | View Filing | |
| form 4 | Form 4 — McDonald Kirk P | View Filing | |
| form 4 | Form 4 — Harrington Michael J | View Filing | |
| form 4 | Form 4 — Harrington Michael J | View Filing | |
| form 4 | Form 4 — Anand Kapila K | View Filing | |
| form 4 | Form 4 — Anand Kapila K | View Filing | |
| form 4 | Form 4 — Ma Stacey | View Filing | |
| form 4 | Form 4 — Ma Stacey | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — VanHimbergen Robert M | View Filing | |
| form 4 | Form 4 — Modi Rajeev A. | View Filing | |
| form 4 | Form 4 — Modi Rajeev A. | View Filing | |
| edgar index | SCHEDULE 13G/A — Elanco Animal Health Inc | View Filing | |
| edgar index | SCHEDULE 13G/A — Elanco Animal Health Inc | View Filing | |
| edgar index | 8-K — Elanco Animal Health Inc | View Filing | |
| edgar index | 10-Q — Elanco Animal Health Inc | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — VanHimbergen Robert M | View Filing | |
| form 4 | Form 4 — Modi Rajeev A. | View Filing | |
| edgar index | SCHEDULE 13G — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — VanHimbergen Robert M | View Filing | |
| form 4 | Form 4 — Modi Rajeev A. | View Filing | |
| edgar index | SCHEDULE 13G/A — Elanco Animal Health Inc | View Filing | |
| edgar index | DEF 14A — Elanco Animal Health Inc | View Filing | |
| edgar index | DEFA14A — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| edgar index | 4 — Elanco Animal Health Inc | View Filing | |
| form 4 | Form 4 — Simmons Jeffrey N | View Filing | |
| form 4 | Form 4 — VanHimbergen Robert M | View Filing |